品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
蚂蚁淘在线 / 品牌中心 / Hycult Biotech / Hycult Biotech/Lectin Complement Pathway, Rat, Assay | Hycult Biotech/HIT411
商品描述
The HIT411 measures the lectin pathway activity mediated via MBL. Complement deficiencies or other defects in the complement system can easily be screened by running an assay for each pathway in parallel or separately. The ELISA contains a positive control based on the Wistar strain which can be used as process control to ensure that the lectin complement cascade has run completely. This positive control cannot be used to determine the level of activation between batches. We advise to include in your study your own reference sample for 100% complement activity and negative control (eg non-preserved activated serum) to determine the level of activation of your samples. Beware that complement activity levels are rat strain dependent and might be affected by the way the samples are collected and processed.The innate immune system is important in the first defense against foreign pathogens. A major component of this response is the complement system. The complement system consist of a complex family of proteins and receptors which are found in the circulation, in tissues and other body-fluids. Nowadays, also several links to the adaptive immunity are described. The system consist of three defined pathways which are activated by a pathway specific panel of molecules. Complement activation proceeds in a sequential fashion through the proteolytic cleavage of a series of proteins leading to the generation of activated products that mediate various biological activities through their interaction with specific cellular receptors and other serum proteins The three pathways, designated classical, lectin and alternative pathway, converge at a central component into a final common pathway. That is activation of C3 leading to formation of C3a and C3b. This cleavage activates the terminal complement pathway leading to eventually the formation of the terminal C5b-9 complement complex (TCC). The classical pathway is initiated by binding of C1q to antibody complexes, whereas the alternative and lectin pathway are activated in an antibody-independent fashion through the interaction of complement components with respectively specific carbohydrate groups and lipopolysaccharides (LPS) on the surface of foreign pathogens. The alternative pathway also acts as an amplification loop of the other pathways.Under certain conditions, the complement system can be unfavorable to the host leading to e.g. autoimmune diseases and infections. Deficiency of C3 is e.g. associated with SLE. Alterations in the alternative pathway, like properdin or ficolin deficiency, increase the susceptibility to infection. Mannose binding lectin (MBL), a major component of the lectin pathway, is associated with bacterial, fungal and viral infection. A common way to measure the activity of the classical or alternative pathway is the haemolysis of erythrocytes. Furthermore some assays have been described to measure the activity of the MBL pathway. Not all assay are easy to perform. The rat pathway ELISAs are easy to use and specific per pathway by making use of a combination of specialized coatings and buffers. Complement deficiencies or other defects in the complement system can easily be screened by running an assay for each pathway in parallel or separately.
Hycult Biotech当您在研究项目中寻找中小企业合作伙伴时,Hycult Biotech是您的首选合作伙伴。凭借我们的背景和专业知识,我们可以为您的项目增值:从成为财团的负责人到成为科学项目的推动力,我们都有在科学项目中扮演不同角色的经验。由于我们遍布全球的广泛网络,我们可以在寻找研究项目的合作伙伴方面发挥核心作用。我们可以协助撰写建议书或建立财团。获得科学资助的我们的研究活动示例:生物标志物测定法的发展抗体的表征。从概念到最终产品。Hycult Biotech代表什么从1994年开始创建分析,抗体和蛋白质。根据ISO13485指南开发和生产(IVD)套件。关于复杂基质中蛋白质难以测量的广泛知识。制药和生物技术行业的伴侣诊断合作伙伴。 Hycult Biotech目前参与以下研究项目OPZuid:Zuid-Nederland行动纲领Hycult Biotech利用“ OP Zuid”资金,目前正在研究开发针对类风湿性关节炎和骨关节炎的创新诊断测试的可能性。使用该测试可以更好地监视患者及其疾病活动,严重程度和治疗反应。更好的诊断结合个性化治疗将大大改善这些患者的生活质量。相关:缓解慢性自身免疫性疾病的预防RELENT项目提供了探索新的研究领域并加深其对自身免疫和炎症领域的见解的机会。Hycult Biotech在该主题非常适合的慢性炎性疾病领域中不断扩展产品。寻找与RA,IBD和AASV相关的新型靶蛋白将为进一步进入诊断领域提供机会。 Hycult Biotech已成功参与以下研究项目-DIREKT:解除血管内固有免疫反应,改善慢性肾脏病的治疗方式-PREDICCt:糖尿病和与糖尿病相关的心血管并发症的预测和早期诊断的生物标志物-TranSVIR:转化为血管炎症和修复的科学-指示:慢性自身免疫的传染性诱因 有关科学赠款和合作的更多信息,请参见以下传单: